Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP688 · 1 trial · 1 indication
Binding of \[11C\]ABP688 will be determined using positron emission tomography (PET) for up to 90 minutes
Blood samples (up to 19 time points via indwelling catheter) will be collected for the determination of \[11C\] ABP688. Specific times are recorded at the clinical site.
| Arm | Type | Description |
|---|---|---|
| ABP688 | EXPERIMENTAL | Elderly MDD patients and demography matched healthy volunteer |
| Name | Type | Description |
|---|---|---|
| ABP688 | DRUG | Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push. |
Inclusion Criteria: * Male and female subjects 55-80 (inclusive) * Subjects in good health At screening: * oral body temperature between 35-37.5C * systolic blood pressure: 90-140 mm Hg * diastolic blood pressure: 50-90 mm Hg * pulse rate: 40-90 bpm * Female subjects of child bearing potential mu...
ABP688 is an investigational small molecule being studied for use in depression. It is a positron emission tomography (PET) radiotracer, labeled with carbon-11, intended to characterize the regional distribution of a target in the brain. It is currently in Phase 1 clinical development and is not approved by the FDA.
ABP688 is a PET radiotracer that binds to metabotropic glutamate receptor subtype 5 (mGluR5). It is used to visualize and characterize the regional distribution of mGluR5 in the brain by positron emission tomography. This target is relevant to psychiatric conditions such as depression.
ABP688 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the drug's use as a PET imaging agent in depression.
ABP688 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed, involving 42 participants, to characterize the regional distribution of the radiotracer in the brain.
ABP688 has one completed clinical trial registered under NCT01528241, titled 'Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)'. This Phase 1 study enrolled 42 participants in the United States, including healthy volunteers aged 55 years and older.